Search Results
Jun 01, 2026, 11:33 ET Camurus announces expansion of Lilly collaboration
class. The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual GLP-1 and GIP and receptor agonists, triple agonists for GLP-1, GIP and glucagon receptor agonists, and amylin receptor agonists."Lilly's decision to exercise the option
More news about: Camurus AB
May 31, 2026, 23:09 ET Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
clinical trials for five other programs utilizing the same platform.Hanmi has focused on the biological functions of glucagon-like peptide 2 (GLP-2) - including the promotion of intestinal growth, reduction of inflammation, and protection and regeneration of the intestinal mucosa - and has demonstrated
More news about: Hanmi Pharm. Co., Ltd.
May 31, 2026, 20:48 ET Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
clinical trials for five other programs utilizing the same platform.Hanmi has focused on the biological functions of glucagon-like peptide 2 (GLP-2) - including the promotion of intestinal growth, reduction of inflammation, and protection and regeneration of the intestinal mucosa - and has demonstrated
More news about: Hanmi Pharm. Co., Ltd.
May 29, 2026, 10:45 ET Kalohexis Announces Publication in Nature Communications Highlighting Dual MC3R/MC4R Activation as a Novel, Durable Mechanism that Drives Weight Loss
selective MC4R agonism, drives enhanced weight loss and reduced food intake while improving upon the limitations of prior MC4R-selective and GLP-1 based approaches. These data provide important insights that support a clear path forward for melanocortin-targeted therapeutics, specifically the
More news about: Kalohexis
May 29, 2026, 09:08 ET Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions
AD, supported by global IP and patent portfolios. Its core product, Efsubaglutide Alfa (a next-generation human-derived ultra-long-acting GLP-1 receptor agonist), is approved for type 2 diabetes in Chinese Mainland and Macau SAR, included in China's National Reimbursement Drug List, and
More news about: Innogen Pharmaceuticals
May 29, 2026, 07:00 ET Alaw Therapeutics Announces Two Major Pipeline Milestones Advancing Brain-Penetrant CDK Oncology Programs
engagement and antitumor activity in CDK4-dependent CNS tumor models.AL-433 has been well tolerated in multi-species preclinical safety studies, and GLP toxicology studies are ongoing in support of clinical advancement. Planned clinical studies are expected to permit enrollment of patients with active
More news about: Alaw Therapeutics
May 28, 2026, 13:00 ET Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
sugar (glucose). As the first and only FDA-approved GIP and GLP-1 receptor agonist, Mounjaro is a single molecule that activates the body's receptors for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is not known if Mounjaro is safe
More news about: Eli Lilly and Company
May 28, 2026, 12:28 ET Parker Waichman LLP Files Lawsuit on behalf of Florida Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic and Mounjaro
Waichman continues to file additional cases and urges individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact them for a
More news about: Parker Waichman LLP
May 28, 2026, 08:00 ET Kalohexis Announces First Patients Dosed in First-in-Human Phase 1 Clinical Trial of 710GO for General Obesity
including nonhuman primates, 710GO's novel mechanism of action demonstrated consistent weight loss and did not cause the side effects common with GLP-1 receptor agonists, such as substantial loss of lean body mass, gastrointestinal distress and rapid weight regain following treatment cessation.
More news about: Kalohexis
May 28, 2026, 06:45 ET CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options
2026, increasing access to GLP-1s at a more affordable price for plan sponsors who elect to provide coverage of those medications for their members. Additionally, effective June 1, 2026, CVS Caremark will remove the new-to-market block on Foundayo™(orforglipron), a new oral GLP-1 therapy, where approved
More news about: CVS Health
May 28, 2026, 06:45 ET Foundayo and Zepbound now covered for millions of Americans
also be eligible to pay $50 per month for their obesity medicines beginning July 1 through the Medicare GLP-1 Bridge program.**Foundayo is the only once-daily GLP-1 pill for weight management that can be taken any time of day without food or water restrictions.1
More news about: Eli Lilly and Company
May 27, 2026, 09:00 ET Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association's 2026 Scientific Sessions
semaglutideSemaglutide is a GLP-1 receptor agonist (GLP-1 RA) that is structurally similar to the naturally occurring hormone GLP-1. It works by selectively binding to and activating the GLP-1 receptor. Semaglutide has been tested in several
More news about: NOVO NORDISK INC.
May 27, 2026, 09:00 ET FIELDS GOOD LAUNCHES COOKIES WITH BENEFITS, BACKED BY $1.8M FROM FEMALE FOUNDERS FUND
the last decade, according to the Global Wellness Institute. Consumers are stacking new priorities, from sleep and protein to focus, longevity, and GLP-1s, into ordinary days alongside the foods they love. Fields Good is built for that consumer: someone who wants a treat, and wants it to count for something.Debut
More news about: Fields Good
May 27, 2026, 08:31 ET MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
(OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR),
More news about: MetaVia Inc.
May 27, 2026, 08:00 ET Le-Vel Brands Launches Le-Vel Rx, A New Era in Access to Telehealth, Prescription Wellness & Longevity Medicine
therapeutics market is experiencing unprecedented growth, driven by surging consumer demand for clinically supervised health solutions. As GLP-1 therapies and prescription peptides dominate national headlines and reshape how Americans approach their health, Le-Vel Rx is positioned to meet
More news about: Le-Vel Brands
May 26, 2026, 18:31 ET Sunlight Launches Sunlight NAD+ Rx, a Clinician-Supervised NAD+ Program Delivered Through Its Clinical Pathway
available to support them."While the physician is supervising one layer of the patient's peptide use, the patient is self-managing other non-GLP-1 products through gray-market channels the physician has no visibility into," said Dr. Angela Tran, MD, board-certified in internal and obesity
More news about: Sunlight.com
May 26, 2026, 13:56 ET The 'Hidden' Side Effect of Weight-Loss Drugs That Could Be Affecting Your Mouth, warns Oralieve
receive GLP-1 treatments in the near term and up to 3.4 million people targeted over the longer term, while private use continues to outpace public provision.Analysis from Oralieve indicates that as more people turn to these medications, 30-40% of GLP-1 users may experience
More news about: Oralieve UK
May 26, 2026, 10:08 ET ILC Dover Expands Life Sciences Presence with Water for Injection (WFI) and Custom Chemical Solutions
GLP‑1 treatments.As demand for GLP‑1 therapies continues to rise globally, manufacturers face increasing pressure to scale safely, efficiently, and compliantly. ILC Dover's specialized solutions for GLP‑1 manufacturing—combined with the new WFI capability
More news about: ILC Dover
May 26, 2026, 10:08 ET ILC Dover amplía su presencia en ciencias biológicas con agua para inyección (WFI) y soluciones químicas personalizadas
tratamientos GLP-1.A medida que la demanda de terapias GLP-1 continúa aumentando a nivel mundial, los fabricantes afrontan una presión cada vez mayor para escalar de manera segura, eficiente y compatible. Las soluciones especializadas de ILC Dover para la fabricación GLP-1, combinadas con
More news about: ILC Dover
May 26, 2026, 09:30 ET Obesity Action Coalition Highlights New Analysis Showing Most Insured Americans Face Barriers to Obesity Medications
million of the 316 million insured individuals in the United States, approximately seven percent, were enrolled in health plans where access to GLP-1 medications for obesity aligned with the FDA-approved indication without additional restrictions.While approximately 104 million insured
More news about: Obesity Action Coalition
May 26, 2026, 09:00 ET As Millions Turn to GLP-1 Medications, Mía Launches a Fiber-First Protein Shake to Close the Fiber Gap
AUSTIN, Texas, May 26, 2026 /PRNewswire/ -- With #fibermaxxing trending and GLP-1 medications reshaping how Americans eat, one nutritional gap remains unaddressed: fiber. Today, that changes. The Fiber Gap95%
More news about: Mía
May 26, 2026, 08:30 ET Deepening Focus on Autoimmune Diseases, Empowering AI-Driven Drug Discovery
facilities accredited by AAALAC for international animal welfare standardsCompliance with animal ethics and welfare regulationsNon-GLP and ICH-guideline-compliant study reports supporting both domestic and international regulatory submissionsHkeyBio also provides transparent
More news about: HKeyBio
May 26, 2026, 08:03 ET Mounting Rx Lawsuits Expose Ongoing Concerns Over FDA's Revolving Door
26, 2026 /PRNewswire/ -- The pharmaceutical industry is no stranger to litigation. For example, more than 3,600 lawsuits involving GLP-1 drugs are currently pending in federal multidistrict litigation alone. What is less known is how the Food and Drug Administration's (FDA) long-debated
More news about: Wisner Baum
May 26, 2026, 07:30 ET Hydreight Technologies Announces Timing of Q1 2026 Financial Results and Investor Webcast
platform is expected to help businesses launch direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy ("TRT"), hair loss, skincare, sexual health and more. Hydreight
More news about: Hydreight Technologies Inc.
May 25, 2026, 04:00 ET sweelin® Approved in Singapore as a Food Additive expanding Amai Proteins' Regulatory Footprint into Asia
Sweet Protein" in the US, supporting consumer-friendly ingredient claims and aligning with the growing demand for Clean-Label and GLP-1-friendly products.Singapore has established itself as a global Food Technology Innovation leader with programs including its "30 by 30" initiative.
More news about: Amai Proteins